Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
about
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapyFunctional characterization of human PFTK1 as a cyclin-dependent kinaseAn oncologist׳s friend: How Xenopus contributes to cancer researchPotent anti-proliferative, pro-apoptotic activity of the Maytenus royleanus extract against prostate cancer cells: evidence in in-vitro and in-vivo modelsTherapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.Arctigenin anti-tumor activity in bladder cancer T24 cell line through induction of cell-cycle arrest and apoptosisCyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycleRegulation of cyclin D2 expression and degradation by follicle-stimulating hormone during rat granulosa cell proliferation in vitroCell proliferation and expression of cell cycle regulatory proteins that control the G1/S transition are age dependent and lobe specific in the Brown Norway rat model of prostatic hyperplasiaA novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIMA limited role for p53 in modulating the immediate phenotype of Apc loss in the intestine.Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cellsCryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation.To develop with or without the prion protein.MicroRNA-25 regulates small cell lung cancer cell development and cell cycle through cyclin E2Overexpression or silencing of FOXO3a affects proliferation of endothelial progenitor cells and expression of cell cycle regulatory proteins.Neuronal cell cycle: the neuron itself and its circumstancesIncreased cyclin-dependent kinase 6 expression in bladder cancer.Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogeneDirect inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes.Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell linesFive years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.New combination therapies with cell-cycle agentsDual control of Shuanghuang Shengbai granule on upstream and downstream signal modulators of CyclinD-CDK4/6 signaling pathway of cell cycle in Lewis-bearing mice with cyclophosphamide-induced myelosuppression.Affinity and dose of TCR engagement yield proportional enhancer and gene activity in CD4+ T cells.Regulation of the retinoblastoma proteins by the human herpesviruses.Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related statesSerum anti-CCNY autoantibody is an independent prognosis indicator for postoperative patients with early-stage nonsmall-cell lung carcinomaThe atypical CDK activator Spy1 regulates the intrinsic DNA damage response and is dependent upon p53 to inhibit apoptosis.Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo.Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates.Distinct proliferative and transcriptional effects of the D-type cyclins in vivo.The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.Human gene control by vital oncogenes: revisiting a theoretical model and its implications for targeted cancer therapy.Cyclin dependent kinases in cancer: potential for therapeutic intervention.Tumor suppressive pathways in the control of neurogenesis.AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.Effect of reversine on cell cycle, apoptosis, and activation of hepatic stellate cells.
P2860
Q21245716-3712F5DE-7629-4717-A6FC-042560CAF46CQ24306566-54877D47-499D-4750-8B50-5CF68E7AF2D3Q26849774-72D30711-36C8-4E21-B963-E3C559417313Q27311628-9CDEDCC9-5D1D-4F07-AD8B-E887B48DC6DAQ27851564-6889CF37-30BF-4156-A61F-BD6692DED882Q28267277-5EF295B7-9960-4D35-B724-D7720E383457Q28268021-E69EEB22-C6D9-4AB8-9C67-15DC33247938Q28571887-5F952EDA-EDB9-4888-B47D-CBBE5D717BF1Q28572109-6FC31C2D-0DDC-4AEF-8856-688F05E2DD59Q30495531-62883AA7-0056-4C24-8B2F-79BF964E63DBQ33336561-62244789-D61B-41D5-A5B2-3EAF60669EF9Q33340817-0602C014-3A74-430C-95D0-0C5CBE94DD54Q33632727-A869F2E0-3C4D-40E3-98A2-D55FC7343968Q34049893-0C76C13F-9B86-49E2-9CBD-15FD265603FFQ34391248-EF3C5CFA-7ECB-4AB1-83E1-27897F358A0FQ34733320-B123684A-A587-43E6-8992-5EFF7367C560Q35219442-1CD3274E-5896-4249-A59D-CEE4A4183A82Q35565056-DFACFD47-4874-4342-B9C9-1E9C280930C1Q36099328-016C9628-323A-4EB5-B397-77A8E157456DQ36413813-9E414398-A0BF-494A-98F4-E0DDD922D2BFQ36419687-7C123D75-3C50-4183-8821-A153736F0237Q36653012-DEA9E2F4-D90F-4086-B9DB-B4A1F196383BQ36716750-F875214B-8A16-4AB6-9319-DF3604CD82E9Q36737314-12DAD84F-D9DF-47A6-92B1-D7C09DA5166CQ36738599-6D11A65B-BF51-478F-BB26-0D5320C221AEQ37062660-0DB82991-ABE1-4E92-88B6-38F5C90E93D0Q37085853-295817FB-4678-44A7-BD1B-1596C97E3780Q37198026-D324DA4A-8900-44EE-8D72-06D53526AFA4Q37212230-4BE68862-4E80-43B9-9E71-EFAB622E06ABQ37435962-82619307-42C1-478A-A99B-FB77C09B8944Q37591650-C6872E35-C916-4FF8-8D7A-1DF059728208Q37718853-EAF6DAA6-8B56-4556-9148-DDB051C133C6Q37724102-1E4A736F-A9BC-4B94-A2F8-C1442432FE70Q37948079-C98FA0B9-8ACC-4A33-B69A-E14F34FBDA8EQ37982050-58773AE7-4ACD-4855-AA90-C2909994C72FQ37987789-096DE571-7CAE-46F6-A168-0C0AF382B648Q38026794-D3491F79-7E1A-44F4-9E35-51C95A9BA9B0Q38597474-3D559D02-03BC-4A5E-B256-14B0FEB19A39Q38675849-14A943AF-5034-4F1D-9171-3BE216926E62Q38733868-83F3B0EA-0052-4780-9993-A49CCE54EC7D
P2860
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
@ast
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
@en
type
label
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
@ast
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
@en
prefLabel
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
@ast
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
@en
P356
P1476
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
@en
P2093
David Santamaria
Sagrario Ortega
P304
P356
10.2741/1871
P577
2006-01-01T00:00:00Z